Want to see TSE:ASEP full AI Analyst Report?
Top Page
ASEP Medical Holdings Inc
(ASEP)
Select Model
Select Model
Rating:42Neutral
Price Target:
C$0.13
▼(-59.68% Downside)
Action:Reiterated
Date:10/11/26
The score is held down primarily by weak financial performance (heavy losses and ongoing cash burn despite low leverage). Technicals add further pressure with a bearish trend (price below key moving averages and negative MACD). Valuation contributes negatively due to a loss-making profile (negative P/E) and no dividend support.
Positive Factors
Low leverage
Very low leverage gives ASEP greater financial flexibility than a heavily indebted early-stage biotech. Limited debt reduces fixed financing pressure and may help the company preserve capital for development, although it does not eliminate the need to fund ongoing operations.
Negative Factors
Persistent cash burn
Ongoing negative operating and free cash flow means ASEP is not yet funding its activities internally. Continued burn can require additional financing or capital consumption, limiting strategic flexibility and increasing the importance of achieving revenue scale or materially reducing expenses.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Very low leverage gives ASEP greater financial flexibility than a heavily indebted early-stage biotech. Limited debt reduces fixed financing pressure and may help the company preserve capital for development, although it does not eliminate the need to fund ongoing operations.
Read all positive factors
ASEP Medical Holdings Inc (ASEP) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$2.06M
Dividend YieldN/A
Average Volume (3M)13.06K
Price to Earnings (P/E)―
Beta (1Y)-1.10
Revenue Growth13.48%
EPS Growth64.30%
CountryCA
Employees6
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.36
Shares Outstanding15,873,520
10 Day Avg. Volume23,034
30 Day Avg. Volume13,059
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.24
Price to Sales (P/S)8.56
P/FCF Ratio-2.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ASEP Medical Holdings Inc Business Overview & Revenue Model
Company Description
Asep Medical Holdings Inc. is dedicated to advancing medical solutions, primarily through its subsidiary, ASEP Medical Inc. The company's core focus involves pioneering an early diagnostic method for Sepsis, as well as developing innovative peptid...
ASEP Medical Holdings Inc Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
28
Negative
| Breakdown | Jun 2026 | Sep 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 336.77K | 297.59K | 21.14K | 0.00 | 0.00 |
| Gross Profit | -374.59K | 297.59K | -113.74K | -155.40K | -177.18K |
| EBITDA | -1.85M | -2.36M | -8.14M | -4.56M | -2.06M |
| Net Income | -4.92M | -8.27M | -8.23M | -5.76M | -2.30M |
Balance Sheet | |||||
| Total Assets | 8.72M | 14.32M | 25.61M | 27.08M | 30.72M |
| Cash, Cash Equivalents and Short-Term Investments | 153.65K | 45.68K | 64.72K | 2.13M | 5.29M |
| Total Debt | 230.00K | 314.82K | 20.00K | 0.00 | 0.00 |
| Total Liabilities | 4.38M | 4.87M | 3.05M | 528.16K | 144.20K |
| Stockholders Equity | 2.33M | 4.94M | 12.61M | 15.47M | 18.26M |
Cash Flow | |||||
| Free Cash Flow | -1.02M | -337.13K | -2.72M | -3.61M | -1.31M |
| Operating Cash Flow | -1.02M | -337.13K | -2.71M | -3.61M | -1.19M |
| Investing Cash Flow | 749.37K | -380.00 | -4.47K | 124.80K | 146.08K |
| Financing Cash Flow | 402.94K | 291.98K | 651.40K | 330.00K | 6.34M |
ASEP Medical Holdings Inc Technical Analysis
Neutral
0.31
Price Trends
0.16
Negative
0.15
Negative
0.21
Negative
Market Momentum
-0.02
Positive
47.54
Neutral
20.00
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ASEP, the sentiment is Neutral. The current price of 0.31 is above the 20-day moving average (MA) of 0.13, above the 50-day MA of 0.16, and above the 200-day MA of 0.21, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 47.54 is Neutral, neither overbought nor oversold. The STOCH value of 20.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:ASEP.
ASEP Medical Holdings Inc Peers Comparison
UnderperformOutperform
Sector (51)
TSE:ASEP
ASEP Medical Holdings Inc
0.13
-0.37
-74.00%
TSE:DRUG
Bright Minds Biosciences
74.67
-21.04
-21.98%
TSE:MYND
MYND Life Sciences
0.07
0.00
0.00%
TSE:IBO
Universal Ibogaine Inc
0.01
0.00
0.00%
TSE:MBIO
Mindbio Therapeutics Corp.
0.12
-3.88
-97.00%
ASEP Medical Holdings Inc Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Asep Medical Launches $900,000 LIFE Financing to Fund Biotech Acquisitions
Positive
Oct 9, 2026
Asep Medical Holdings Inc. plans to raise up to $900,000 through a non-brokered private placement under the Listed Issuer Financing Exemption, offering 9,000,000 units at $0.10 each, with attached warrants exercisable at $0.12 for 24 months. The f...
Business Operations and StrategyPrivate Placements and Financing
Asep Medical Launches $900,000 LIFE Financing to Fuel Biotech Portfolio Growth
Positive
Oct 9, 2026
Asep Medical Holdings Inc. plans to raise up to $900,000 through a non-brokered private placement under the Listed Issuer Financing Exemption, offering 9,000,000 units at $0.10 per unit, each comprising one common share and a warrant exercisable a...
Business Operations and StrategyPrivate Placements and Financing
Asep Medical Secures US$1 Million Loan to Fund Operations
Positive
Oct 9, 2026
Asep Medical Holdings Inc. has secured a non-revolving term loan facility of US$1 million from an arm’s length private lender to support short-term working capital, operating expenses and general corporate purposes. The loan, bearing 12% ann...
Business Operations and StrategyPrivate Placements and Financing
Asep Medical Retires Insider Debt via Share Issuance
Positive
Oct 2, 2026
Asep Medical Holdings Inc. has closed an agreement to settle CAD$288,250 in outstanding fees owed to creditors, directors, officers and advisors by issuing 2,882,500 common shares at a deemed price of CAD$0.10 per share. The share issuance remains...
Business Operations and StrategyPrivate Placements and Financing
Asep Medical Settles $288,500 in Debt Through Share Issuance
Positive
Sep 18, 2026
Asep Medical Holdings Inc., a biotech-focused investment issuer based in Victoria, BC, leverages a portfolio of patented diagnostic and therapeutic technologies developed at the University of British Columbia. Its key holdings include Sepset Biosc...
Business Operations and StrategyDelistings and Listing Changes
Asep Medical Restructures Stakes in ABT and Sepset While Preserving Economic Upside
Positive
Sep 5, 2026
Asep Medical Holdings Inc., a biotechnology-focused investment issuer based in Victoria, BC, concentrates on diagnostic and therapeutic medical technologies, including sepsis diagnostics through Sepset Biosciences and anti-biofilm solutions via AB...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.